Everything below concerns Salvage pathway. We keep the language plain, cite what the science says, and separate well-supported claims from open questions.
Last reviewed on 2026-08-01. Where a claim depends on a specific study, the study is described rather than over-claimed.
Nicotinamide mononucleotide, abbreviated NMN, is a naturally occurring nucleotide found in the cells of many organisms, including bacteria, plants, and mammals. Its structure consists of a nicotinamide ring attached to a ribose-phosphate group. NMN functions as an intermediate in the NAD+ salvage pathway, a recycling route that regenerates nicotinamide adenine dinucleotide. The enzyme nicotinamide phosphoribosyltransferase produces NMN from nicotinamide and phosphoribosyl pyrophosphate. A second enzyme, NMN adenylyltransferase, then converts NMN into NAD+.
Dietary sources of NMN include small amounts in certain vegetables, fruits, and other foods, although exact values vary by sample and method. Endogenous NMN concentrations are tightly regulated and often low, making measurement in blood or tissues technically demanding. After oral intake, NMN is thought to be rapidly metabolized in the intestine and liver, and intact NMN may not reach all tissues at high levels. Some rodent studies report increases in tissue NAD+ after oral NMN, while human data remain limited and sometimes rely on blood NAD+ metabolites rather than direct tissue measures.
Research on NMN has focused on aging, metabolic regulation, exercise capacity, and insulin sensitivity, but findings are preliminary. Many human trials are small, short in duration, and use different endpoints, which complicates comparison across studies. No national regulator has approved NMN as a therapeutic drug for any indication. In some countries it is sold as a supplement or research chemical, while other jurisdictions have questioned its status under food or supplement laws. Claims about extending human lifespan or reversing aging are not supported by established clinical evidence.
Nicotinamide mononucleotide, abbreviated NMN, is a naturally occurring nucleotide. Its structure combines a nicotinamide base with a ribose sugar and a phosphate group. Within cells, NMN sits on the biosynthetic route that recycles nicotinamide back into nicotinamide adenine dinucleotide, or NAD+. Because NAD+ participates in redox reactions and signaling, enzymes that produce and consume it influence many metabolic processes. The compound is therefore best described as an intermediate rather than a final signaling molecule.
In the canonical salvage pathway, nicotinamide phosphoribosyltransferase, known as NAMPT, transfers a phosphoribosyl group to nicotinamide and releases NMN. A second enzyme, NMN adenylyltransferase, then attaches an adenylyl group to NMN to form NAD+. Alternative routes exist, including a pathway that uses nicotinamide riboside and its phosphorylated forms. The relative contribution of extracellular NMN to intracellular NAD+ pools remains an area of active investigation, and the roles of specific transporters and enzymes are not completely defined.
| Property | Value | Notes |
|---|---|---|
| Chemical name | Nicotinamide mononucleotide | Nucleotide intermediate in NAD+ salvage pathway |
| Common abbreviation | NMN | Also written as β-NMN |
| Molecular formula | C11H15N2O8P | Uncharged parent form |
| Molar mass | 334.22 g/mol | Calculated from formula |
| CAS Registry Number | 1094-61-7 | For β-nicotinamide mononucleotide |
Nicotinamide mononucleotide, abbreviated NMN, is a nucleotide composed of nicotinamide, ribose, and phosphate. Its structure links nicotinamide to D-ribose 5-phosphate through a glycosidic bond, placing it in the pyridine nucleotide family. The compound exists in alpha and beta anomeric forms, and the beta form is the one used in NAD+ biosynthesis. NMN is not a protein or a hormone; it is a small water-soluble molecule that occurs in living cells as a metabolic intermediate.
Natural sources of NMN include mammals, plants, and microorganisms, where it functions as an intermediate in NAD+ salvage and biosynthesis pathways. In mammals, the enzyme nicotinamide phosphoribosyltransferase produces NMN from nicotinamide and phosphoribosyl pyrophosphate. NMN is then converted to NAD+ by nicotinamide mononucleotide adenylyltransferase. Some foods contain measurable NMN, but reported amounts vary widely by species, tissue, and analytical method. The extent to which dietary NMN contributes to cellular NAD+ pools remains an open research question.
In the NAD+ salvage pathway, the enzyme NAMPT converts nicotinamide and a phosphate-donor molecule into NMN. A second enzyme, NMNAT, then converts NMN into NAD+. Nicotinamide riboside can also enter this route after being converted to NMN by nicotinamide riboside kinases. Because NMN sits at a junction between precursor uptake and NAD+ formation, its cellular concentration is tightly linked to enzyme activity and tissue type. NAD+ participates in redox reactions, signaling, and DNA repair, and its levels decline with age in some animal models, though human evidence remains more limited and context-dependent.
Research interest in NMN increased after animal studies reported that oral or injected NMN can raise NAD+ levels in some tissues. How NMN is absorbed and distributed in humans is not fully established. Some evidence suggests extracellular NMN may be dephosphorylated to nicotinamide riboside before cellular uptake, while other studies propose specific transport routes. Direct human data on these mechanisms remain limited. Regulatory status also varies: in some countries NMN is treated as a dietary supplement, while elsewhere it is restricted or requires approval, and these differences affect labeling, sale, and research.
Nicotinamide mononucleotide, commonly abbreviated NMN, is a pyridine nucleotide that consists of a nicotinamide ring, a ribose sugar, and a phosphate group. It is an intermediate in the salvage pathway for nicotinamide adenine dinucleotide, or NAD+, synthesis. In mammalian cells, the enzyme nicotinamide phosphoribosyltransferase produces NMN from nicotinamide and phosphoribosyl pyrophosphate. Nicotinamide mononucleotide adenylyltransferases then convert NMN into NAD+. The core structure and enzymatic route are well established in biochemical literature.
The biologically relevant form of NMN is generally the beta anomer, which is recognized by NMN adenylyltransferases. NMN is polar and water soluble, and it does not readily diffuse across lipid membranes without assistance. Whether intact NMN enters cells through a specific transporter remains an open question; some studies propose solute carrier family members, while other work favors extracellular dephosphorylation to nicotinamide riboside followed by uptake. This transport and compartmentalization debate affects how researchers interpret oral administration studies. The distinction between intracellular synthesis and extracellular delivery is central to current discussion.
Terminology around NMN can be confusing because several related compounds share the vitamin B3 family. Nicotinamide riboside is a nucleoside, whereas NMN is a nucleotide with a phosphate group, and NAD+ is a dinucleotide coenzyme rather than a simple precursor. Niacin and nicotinamide are also NAD+ precursors but follow different metabolic entry points. In commercial and scientific writing, NMN usually refers to beta-nicotinamide mononucleotide unless another form is specified. Consistent nomenclature helps distinguish chemical identity from proposed biological effects.
Nach Ausbruch des Ersten Weltkriegs war Emil Fischer einer der ersten Unterzeichner des polemischen Manifests der 93 vom 4. Oktober 1914, das den Einmarsch deutscher Truppen in Belgien rechtfertigte. Während des Ersten Weltkriegs war Emil Fischer in einer Vielzahl von Komitees und Ausschüssen aktiv, die sich mit der Sicherung und Entwicklung kriegswichtiger Rohstoffe, Ersatzstoffe und Ernährungsfragen beschäftigten. Dabei übernahm er meist leitende Funktionen und brachte seine wissenschaftliche Expertise gezielt in die praktische Umsetzung ein. Seine Arbeit in diesen Gremien war für die deutsche Kriegswirtschaft und die wissenschaftliche Bewältigung von Versorgungsengpässen von entscheidender Bedeutung. Dazu gehörten einige, deren Aufgabe und Zusammensetzung nach Möglichkeit geheim gehalten wurden, wie die 1916 gegründete Kaiser-Wilhelm-Stiftung für kriegstechnische Wissenschaft (KWKW). Dort nahm er eine führende Rolle als Vorsitzender des Fachausschusses für chemische Rohstoffe ein. Er war maßgeblich an der Organisation, der Wahrung der wissenschaftlichen Unabhängigkeit und der praktischen Umsetzung der Forschungsaufgaben beteiligt. Er war Mitglied der Kommission zur Beschaffung von Kokereiprodukten. Diese sollte die Versorgung mit Aromaten sicherstellen. In den Kokereien, die heimische Kohle verarbeiteten, förderte er daher die Installation von Gaswäschern, die Toluol und Benzol absorbierten, und verringerte so die Abhängigkeit von importiertem Erdöl für die Herstellung des Sprengstoffs Trinitrotoluol (TNT) und von Treibstoff für den militärischen Fuhrpark.
Weitere Kommissionen hatten den Auftrag, die Sicherung der Schwefelversorgung zu untersuchen, die Herstellung von Fettsäureestern und deren Verwendung, insbesondere zur Margarineproduktion zu fördern und die Produktion von Stickstoffdüngern zu erhöhen. Der Nährstoffausschuss hatte die Aufgabe, die wissenschaftliche Bearbeitung der Nahrungsbeschaffung für Mensch und Tier zu übernehmen. Der Ausschuss arbeitete bis November 1918 an Lösungen für Ernährungsprobleme, wie die Umwandlung von Stroh in Tierfutter und die Entwicklung von Ersatznahrungsmitteln.
Zu seinen Aufgaben gehörte ebenfalls die Sicherstellung ausreichender Mengen an Sprengstoff und dessen Vorprodukt Salpeter. Zu Beginn des Krieges wies Fischer zusammen mit Walther Rathenau auf die wehrwirtschaftliche Notwendigkeit der Salpeterproduktion hin, womit er sich einen Verweis wegen Einmischung in interne militärische Angelegenheiten einhandelte. In enger Abstimmung mit Carl Duisberg, dem Vorstandsvorsitzenden von Bayer, trieb er gleich nach Kriegsausbruch ein Abkommen mit Unternehmen wie Bayer, BASF und Hoechst voran, das Mitte Januar 1915 unterzeichnet wurde. Die Berliner Illustrirte Zeitung lobte: „Emil Fischer steht als weitblickender Berater der Kriegs-Rohstoffabteilung zur Seite.“ Bisher importierter Natur-Kautschuk wurde dank seiner Initiative zunehmend durch synthetischen Methylkautschuk ersetzt. Ende 1914 begann die Suche nach tödlichen Giften für den Gaskrieg. An der Entwicklung chemischer Kampfstoffe war Fischer nur anfänglich und am Rande beteiligt. So stellte er im Dezember 1914 „wasserfreie Blausäure“ für Walther Nernst her, der Fischer darum gebeten hatte. Als Nernst die von Fischer hergestellte Blausäure in Versuchen mit Kaninchen ausprobierte, erwies sie sich als weitgehend wirkungslos. Am 18. Dezember wollte Kriegsminister Erich von Falkenhayn in einem Gespräch mit Fischer wissen, ob es etwas gibt, „was die Menschen dauernd kampfunfähig macht“.
Sources: de.wikipedia.org
Fischer erklärte dem Minister, es sei schwierig, Stoffe zu finden, die bei den starken Verdünnungen im Gefechtsfeld noch tödlich wirkten, so Fischer in einem Brief an Duisberg, mit dem er zu jener Zeit korrespondierte. Nach Fritz Habers Versuchen mit Chlorgas wurde dieses tödliche Gift erstmals im April 1915 im Krieg eingesetzt (Zweite Flandernschlacht). Fischer sah darin nichts Verwerfliches und riet seinem Sohn Hermann am 13. Juli 1915:
Sources: de.wikipedia.org
NMN is nicotinamide mononucleotide, a nucleotide intermediate in the NAD+ salvage pathway. Cells use it to help regenerate NAD+, a coenzyme involved in energy metabolism and cellular signaling. It is present naturally in many organisms and is also produced synthetically for research and consumer products.
NMN is the immediate precursor to NAD+ in the salvage pathway. The enzyme NMN adenylyltransferase adds an adenylate group to NMN to form NAD+. Because NAD+ levels decline with age in some tissues, researchers study whether raising NMN availability can influence NAD+ metabolism.
No. Human evidence is limited, and no regulatory agency has approved NMN for treating or preventing aging. Some trials measure NAD+ metabolites or metabolic markers, but their results do not establish a clinical benefit. Larger, longer studies with standardized endpoints are needed.
NMN is nicotinamide mononucleotide, a nucleotide intermediate in NAD+ biosynthesis. It occurs naturally in cells and is also produced commercially as a supplement ingredient.